Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: Serum resistance and antibody response

Immunological Investigations

Volumn 37, Issue 1, 2008, Pages 19-27

  Savoia, D ^a   Deplano, C ^a   Zucca, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antibody response; B. cenocepacia; Cystic fibrosis; ELISA; P. aeruginosa; Serum resistance

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BURKHOLDERIA CENOCEPACIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERUM;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; COMPLEMENT SYSTEM PROTEINS; CYSTIC FIBROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNE SERA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 38549127234     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130701741775     Document Type: Article

References (22)

1. Butler, S. L., Nelson, J. W., Poxton, I. R., Govan, J. R. W. (1994). Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS Immunol. Med. Microbiol. 8:285-292.
2. Bylund, J., Burgess, L. A., Cescutti, P., Ernst, R. K., Speert, D. P. (2006). Exopolysaccharides from Burkholderia cenocepacia inhibit neutrophil chemotaxis and scavenge reactive oxygen species. J. Biol. Chem. 281: 2526-2532.
3. Chiarini, L., Bevivino, A., Dalmastri, C., Tabacchini, S., Visca, P. (2006). Burkholderia cepacia complex species: health hazards and biotechnological potential. Trends Microbiol. 14: 277-286.
4. Cofano, F., Savoia, D., Angeretti, A., Cavallo, G., Landolfo, S. (1985). Production of monoclonal antibodies against the carbohydrate of group A streptococci. Microbiologica 8: 23-30.
5. Conway, B. A., Chu, K. K., Bylund, J., Altman, E., Speert, D. P. (2004). Production of exopolysaccharide by Burkholderia cenocepacia results in altered cell-surface interactions and altered bacterial clearance in mice. J. Infect. Dis. 190: 957-966.
6. Corech, R., Rao, A., Laxova, A., Moss, J., Rock, M. J., Li, Z., Kosorok, M. R., Splaingard, M. L., Farrell, P. M., Barbieri, J. T. (2005). Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J. Clin. Microbiol. 43: 3956-3962.
7. Cripps, A. W., Peek, K., Dunkley, M., Vento, K., Marjason, J. K., McIntyre, M. E., Sizer, P., Croft, D., Sedlak-Weinstein, L. (2006). Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect. Immun. 74: 968-974.
8. Davies, J., Neth, O., Alton, E., Klein, N., Turner, M. (2000). Differential binding of mannose-binding lectin to respiratory pathogens in cystic fibrosis. Lancet 355: 1885-1886.
9. Davies, J., Turner, M., Klein, N. (2001). The role of the collectin system in pulmonary defence. Paediatr. Respir. Rev. 2: 70-75.
10. Hassan, J., Feighery, C., Bresnihan, B., Keogan, M., Fitzgerald, M. X., Whelan, A. (1994). Serum IgA and IgG subclasses during treatment for acute respiratory exacerbation in cystic fibrosis; analysis of patients colonised with mucoid or non-mucoid strains of Pseudomonas aeruginosa. Immunol. Invest. 23: 1-13.
11. Hendry, J., Nixon, L., Dodd, M., Elborn, J. S., Govan, J., Shale, D. J., Webb, A. K. (2000). Pulmonary function, serum markers of inflammation, and IgG antibodies to core lipopolysaccharide of Burkholderia cepacia in adults with cystic fibrosis, following colonization with Burkholderia cepacia. Pediatr. Pulmonol. 29: 8-10.
12. Holder, I. A. (2001). Pseudomonas vaccination and immunotherapy: an overview. J. Burn Care Rehabil. 22: 311-320.
13. Kappler, M., Kraxner, A., Reinhardt, D., Griese, M., Ganster, B., Lang, T. (2006). Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 61: 684-688.
14. Lacy, D. E., Smith, A. W., Lambert, P. A., Peckham, D., Stableforth, D. E., Smith, E. G., Desai, M., Weller, P. H., Brown, M. R. W. (1997). Serum IgG response to an outer membrane porin protein of Burkholderia cepacia in patients with cystic fibrosis. FEMS Immunol. Med. Microbiol. 17: 87-94.
15. Nelson, J. W., Butler, S. L., Brown, P. H., Greening, A. P., Govan, J. R. W. (1993). Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J. Med. Microbiol. 39: 39-47.
16. Pier, G. (2005). Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev. Vaccines 4: 645-656.
17. Pressler, T., Frederiksen, B., Skov, M., Garred, P., Koch, C., Hoiby, N. (2006). Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection - A case control study. J. Cystic Fibrosis 5: 9-15.
18. Richau J. A., Leitao, J. H., Sa-Correia I. (2000). Enzymes leading to the nucleotide sugar precursors for exopolysaccharide synthesis in Burkholderia cepacia. Biochem. Biophys. Res. Commun. 276: 71-76.
19. Sedlak-Weinstein, E., Cripps, A. W., Kyd, J. M., Foxwell, A. R. (2005). Pseudomonas aeruginosa: the potential to immunize against infection. Expert Opin. Biol. Therap. 5: 967-982.
20. Trautmann, M., Bauer, C., Schumann, C., Hahn, P., Hoher, M., Haller, M., Lepper, P. M. (2006). Common RAPD pattern of Pseudomonas aeruginosa from patients and tap water in a medical intensive care unit. Int. J. Hyg. Environ. Health 209: 325-331.
21. Vitkauskiene, A., Scheuss, S., Sakalauskas, R., Dudzevicious, V., Sahly, H. (2005). Pseudomonas aeruginosa strains from nosocomial pneumonia are more serum resistant than P. aeruginosa strains from noninfectious respiratory colonization processes. Infection 33: 356-361.
22. Zuercher, A. W., Horn, M. P., Que, J. U., Ruedeberg, A., Schoeni, M. H., Schaad, U. B., Marcus, P., Lang, A. B. (2006). Antibody response induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. FEMS Immunol. Med. Microbiol. 47: 302-308.